GEP20001940B - Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment - Google Patents

Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Info

Publication number
GEP20001940B
GEP20001940B GEAP19963845A GEAP1996003845A GEP20001940B GE P20001940 B GEP20001940 B GE P20001940B GE AP19963845 A GEAP19963845 A GE AP19963845A GE AP1996003845 A GEAP1996003845 A GE AP1996003845A GE P20001940 B GEP20001940 B GE P20001940B
Authority
GE
Georgia
Prior art keywords
treatment
processes
producing
crystalline form
anhydrous crystalline
Prior art date
Application number
GEAP19963845A
Other languages
English (en)
Inventor
James Wotrap David
David Michael Skinner
Philip George Lake
Gregory Alan Conway
William Bayne Grubb Iii
Richard Augustus Winnike
Peter Gregory Varlashkin
Jane Muse Partin
Barry Howard Carter
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20001940(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of GEP20001940B publication Critical patent/GEP20001940B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GEAP19963845A 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment GEP20001940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
GEP20001940B true GEP20001940B (en) 2000-02-05

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19963845A GEP20001940B (en) 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment

Country Status (40)

Country Link
US (1) US6107302A (en:Method)
EP (1) EP0804436B1 (en:Method)
JP (1) JP3176633B2 (en:Method)
KR (1) KR100376074B1 (en:Method)
CN (1) CN1049893C (en:Method)
AP (1) AP662A (en:Method)
AR (1) AR002270A1 (en:Method)
AT (1) ATE302777T1 (en:Method)
AU (1) AU702794B2 (en:Method)
BG (1) BG63393B1 (en:Method)
BR (1) BR9606768A (en:Method)
CA (1) CA2210799C (en:Method)
CY (1) CY2531B1 (en:Method)
CZ (1) CZ297065B6 (en:Method)
DE (1) DE69635106T2 (en:Method)
DK (1) DK0804436T3 (en:Method)
EA (1) EA000364B1 (en:Method)
EE (1) EE03528B1 (en:Method)
ES (1) ES2248806T3 (en:Method)
FI (1) FI973063L (en:Method)
GB (1) GB9501178D0 (en:Method)
GE (1) GEP20001940B (en:Method)
HR (1) HRP960024B1 (en:Method)
HU (1) HU222993B1 (en:Method)
IL (1) IL116831A (en:Method)
IN (1) IN182468B (en:Method)
IS (1) IS2268B (en:Method)
NO (1) NO315558B1 (en:Method)
NZ (1) NZ298851A (en:Method)
OA (1) OA10499A (en:Method)
PL (1) PL182175B1 (en:Method)
RO (1) RO118693B1 (en:Method)
RS (1) RS49518B (en:Method)
SI (1) SI0804436T1 (en:Method)
SK (1) SK285329B6 (en:Method)
TR (1) TR199700656T1 (en:Method)
UA (1) UA46001C2 (en:Method)
UY (1) UY25779A1 (en:Method)
WO (1) WO1996022291A1 (en:Method)
ZA (1) ZA96449B (en:Method)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
CA2465420A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh) * 2001-11-14 2007-03-28 特瓦制药工业有限公司 伐昔洛韦的合成与纯化
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
CA2527708A1 (en) 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
SK96597A3 (en) 1998-02-04
SI0804436T1 (sl) 2006-02-28
FI973063A0 (fi) 1997-07-18
OA10499A (en) 2002-04-10
IS2268B (is) 2007-07-15
WO1996022291A1 (en) 1996-07-25
CY2531B1 (en) 2006-04-12
AP662A (en) 1998-08-19
UA46001C2 (uk) 2002-05-15
EE03528B1 (et) 2001-10-15
NO973326D0 (no) 1997-07-18
EE9700175A (et) 1998-02-16
HUP9801836A3 (en) 1999-06-28
RO118693B1 (ro) 2003-09-30
AR002270A1 (es) 1998-03-11
BR9606768A (pt) 1997-12-30
IS4527A (is) 1997-07-15
IL116831A (en) 1998-10-30
CA2210799A1 (en) 1996-07-25
EA199700124A1 (ru) 1997-12-30
UY25779A1 (es) 2000-08-21
HRP960024B1 (en) 2005-08-31
AP9701058A0 (en) 1997-10-31
CA2210799C (en) 2008-06-10
HU222993B1 (hu) 2004-01-28
EA000364B1 (ru) 1999-06-24
MX9705462A (es) 1997-10-31
DK0804436T3 (da) 2005-12-27
TR199700656T1 (xx) 1998-03-21
SK285329B6 (sk) 2006-11-03
AU4453996A (en) 1996-08-07
CZ229497A3 (en) 1997-12-17
ATE302777T1 (de) 2005-09-15
PL321326A1 (en) 1997-12-08
HUP9801836A2 (hu) 1999-05-28
JP3176633B2 (ja) 2001-06-18
KR100376074B1 (ko) 2003-06-02
US6107302A (en) 2000-08-22
FI973063A7 (fi) 1997-09-18
DE69635106T2 (de) 2006-06-08
KR19980701525A (ko) 1998-05-15
ZA96449B (en) 1996-08-07
AU702794B2 (en) 1999-03-04
EP0804436B1 (en) 2005-08-24
ES2248806T3 (es) 2006-03-16
EP0804436A1 (en) 1997-11-05
BG101833A (bg) 1998-04-30
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
CN1179159A (zh) 1998-04-15
YU3396A (sh) 1998-12-23
DE69635106D1 (de) 2005-09-29
JPH11503718A (ja) 1999-03-30
FI973063L (fi) 1997-09-18
IL116831A0 (en) 1996-05-14
NZ298851A (en) 1999-01-28
CZ297065B6 (cs) 2006-08-16
IN182468B (en:Method) 1999-04-17
NO315558B1 (no) 2003-09-22
RS49518B (sr) 2006-10-27
NO973326L (no) 1997-09-16
GB9501178D0 (en) 1995-03-08
HRP960024A2 (en) 1997-10-31
PL182175B1 (pl) 2001-11-30

Similar Documents

Publication Publication Date Title
GEP20001940B (en) Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment
CA2213339A1 (en) Method of treating adenosine depletion
HU913396D0 (en) Process for the production of azasteroide compounds and medical preparations containing them as active agents
MY114132A (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
ATE198891T1 (de) Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
HU9600957D0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
PH30250A (en) Substituted cyclohexane derivatives processes for their preparation and the use of the compounds for treating diseases
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
ES8304969A1 (es) Procedimiento para la obtencion de 2-aril-3,4-diazabiciclo 4.n.0-alq-2-en-5-onas.
ES8607916A1 (es) Un procedimiento para la preparacion de medicamentos influenciadores de la circulacion sanguinea, que contienen compuestos de bis (carboxamida)
IL85932A (en) 1-pyridyl (or pyrimidyl)-4-diphenylbutyl piperazines, process for their preparation and pharmaceutical compositions containing them
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
FR2651769B1 (fr) Procede de traitement, par fermentation anaerobie, d'eaux residuaires en vue de l'elimination de la matiere organique et des sulfates qu'elles contiennent.
DE69103087D1 (de) N-substituierte Trifluormethylphenyltetrahydropyridine, Verfahren zur Herstellung, Zwischenprodukte, sowie Arzneimittel, die solche enthalten.
MD1687F2 (en) Arylthiocompounds, pharmaceutical composition, methods of bacterial and viral infections treatment
HUT45250A (en) Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
FR2682950B1 (fr) Procede d'elimination de la diethanolamine presente dans la triethanolamine et procede de preparation de triethanolamine purifiee.
GR900100332A (en) Process for preparation of phenoxypropanolamines pharmaceutical compositions containing them and their use as antiobesity agents
FR2412562A1 (fr) Nouveaux derives de 6'-epi-fortimicines a et b utiles notamment comme agents antibacteriens, procede et intermediaires pour leur preparation et composition pharmaceutique les contenant
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия